AbbVie Inc. ABBV

AbbVie’s strongest current source-backed story is the first-quarter filing: the 10-Q for the period ended 2026-03-31 shows revenues of $15.00B, operating income of $3.99B, net income attributable to parent of $695.0M and diluted EPS of $0.39. The same filing shows $9.39B of cash and cash equivalents and $136.46B of assets, while stockholders' equity attributable to parent stood at $-6.66B. This is a large operating business, not a thin narrative, but the balance sheet still asks hard questions.

AbbVie is an equity claim on a pharmaceutical company whose products move through a concentrated U.S. distribution channel. The 10-Q says AbbVie distributes pharmaceutical products in the United States principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, patients or other customers. It also says three U.S. wholesalers accounted for 78% of total net accounts receivable at 2026-03-31 and 84% at 2025-12-31, and that substantially all U.S. pharmaceutical product net revenues were to those three wholesalers. The operating story therefore runs through medicines, wholesalers, receivables and product economics, not just ticker sentiment.

The latest filed financial rail is mixed in a precise way. AbbVie reported Revenue from Contract with Customer, Excluding Assessed Tax of $61.16B in the 10-K for the period ending 2025-12-31. For the 10-Q period ending 2026-03-31, the company reported net cash provided by operating activities of $3.83B, payments to acquire property, plant and equipment of $265.0M, inventory, net, of $5.05B, and an increase in inventories of $184.0M. The diluted weighted average share count was 1.77B shares. Short-term investments were $28.0M in the 10-K for the period ending 2025-12-31.

The supplied rail does not include a TradingView route, chart levels, volume data or price action, so this report should not pretend to see candles. The market mechanism that can be described from the sources is the business mechanism: product revenue, operating cash flow, inventory, capex, receivables concentration and SEC disclosure cadence. The chart rail can show market context in the rendered page, but the written source pack here proves filings and distribution facts, not technical levels.

The named public developments since late April are filing-led. AbbVie issued an 8-K on 2026-04-29 saying it announced financial results for the first quarter ended 2026-03-31. The 10-Q followed on 2026-05-08. On 2026-05-12, AbbVie filed an 8-K stating stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, and three Form 4 filings also appeared that day. A Form 144 was filed on 2026-05-26, and a Form SD was filed on 2026-06-01, stating that the conflict minerals report for the year ended 2025-12-31 was attached as Exhibit 1.01 and available on AbbVie’s website at investors.abbvie.com.

The official product and employment agreement rail supplied here is narrow. It includes Venclexta royalty treatment outside the United States, where royalties paid for Venclexta revenues outside the United States are included in AbbVie’s cost of products sold, and it includes confidentiality and employee service language from an official AbbVie exhibit. It does not supply a product approval, launch, trial result, guidance figure, dividend update or share repurchase number. The absence matters because it keeps the file grounded in what is filed, not what a reader might expect a large pharmaceutical report to contain.